PDCD1 and colorectal carcinoma: These differences in response to anti-PDCD1 therapy could lead to the emergence of therapeutic approaches using gut microbiota, thereby increasing the effectiveness of cancer immunotherapy in CRC patients with MMR by regulating the composition of the intestinal flora (202, 203).